Fig. 7.

PARP inhibition suppresses the activation of GTPases in monocytes and decreases cytoskeletal changes. Monocytes were pretreated with PARPi (olaparib or talazoparib) or RhoA or Rac1 inhibitor (CT04, NSC23766) before stimulation by MCP-1. a F/G actin ratio in monocytes treated with PARP inhibitors or RhoA/Rac1 inhibitors. G-LISA was used to measure RhoA (b) and Rac1 GTPase activity (c) in cell lysates prepared from the monocytes. The level of RhoA or Rac1 activity in non-stimulated, non-treated cells was assigned a value of 1. Results are shown as the mean ± SEM (*P < 0.5, **P < 0.05 vs. untreated control) from three independent experiments